Helical Tomotherapy in Multiple Myeloma
NCT05970198 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 58
Last updated 2023-08-01
Summary
To explore the safety and efficacy of systemic radiotherapy (TBI) combined with melphalan (Mel) for pretreatment of autologous hematopoietic stem cells in multiple myeloma.
Conditions
Interventions
- RADIATION
-
Total Marrow irradiation,TMI
TMI radiation dose On the 5th day (-5 days) before transplantation, an irradiation dose of 8 Gy is given. TMI uses a 6-18MV linear accelerator, the patient lies on his side in a single irradiation field, covered with a 1 cm thick plexiglass frame, and the radioactive source is 4 meters away from the body surface of the human side. The anterior and anterior positions were alternately irradiated, and the horizontal beam was irradiated in the opposite direction, and the actual irradiation dose was detected by the thermo-optical element of the 2570 roentgen dosimeter scale, and the irradiation dose of all parts of the body was adjusted to make the abdominal irradiation dose difference within 10%, the total dose was 8Gy, divided into 2 times a day, with an interval of 5 hours, and the dose rate was 4.99-6.96cGy/min.
- PROCEDURE
-
Autologous hematopoietic stem cell transplantation
Autologous hematopoietic stem cell transplantation;Porting method melphalan
Sponsors & Collaborators
-
Fuling Zhou
lead OTHER
Principal Investigators
-
Fuling Zhou · Wuhan University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2023-06-14
- Primary Completion
- 2027-12-31
- Completion
- 2027-12-31
Countries
- China
Study Locations
More Related Trials
-
Melphalan and Radiation Therapy Followed By Lenalidomide in Treating Patients Who Are Undergoing Autologous Stem Cell Transplant for Stage I, Stage II, or Stage III Multiple Myeloma
NCT00112827 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT01936090 ·Status: COMPLETED ·Phase: PHASE1
-
Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma
NCT00995059 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Multiple Myeloma Outcomes Based on Maintenance Therapy Post Autologous Stem Cell Transplant
NCT05271630 ·Status: ACTIVE_NOT_RECRUITING
-
Autologous Transplant for Multiple Myeloma
NCT00177047 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
NCT05486975 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
NCT05855122 ·Status: UNKNOWN ·Phase: PHASE4
-
Assessment of Allogeneic Hematopoietic Cell Transplantation in Medicare Beneficiaries With Multiple Myeloma
NCT03127761 ·Status: RECRUITING
-
Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma
NCT00948922 ·Status: COMPLETED ·Phase: PHASE2
-
Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients
NCT02981199 ·Status: UNKNOWN ·Phase: NA
-
Safety and Efficacy Study of High Dose Melphalan to Treat Multiple Myeloma
NCT01572688 ·Status: UNKNOWN ·Phase: NA
-
Total Marrow Irradiation With High Dose Melphalan Prior to Autologous Transplant for Multiple Myeloma
NCT02043860 ·Status: TERMINATED ·Phase: PHASE1
-
Stem Cell Transplant and Zoledronic Acid Improve Outcome in Previously Untreated Patients With Multiple Myeloma
NCT01234129 ·Status: COMPLETED
-
T Cell Immunotherapy for Multiple Myeloma Patients Undergoing a Bone Marrow Transplant
NCT00048464 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Pethema Multiple Myeloma 2000
NCT00560053 ·Status: COMPLETED ·Phase: PHASE3
-
TMI With HD Mel in ASCT for R/R Multiple Myeloma (BMT-03)
NCT02043847 ·Status: COMPLETED ·Phase: PHASE1
-
Mobilization of Stem Cells With Motixafortide (BL-8040) in Combination With G-CSF in Multiple Myeloma Patients
NCT06514508 ·Status: RECRUITING ·Phase: PHASE3
-
Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell Therapy for Relapsed Refractory Multiple Myeloma
NCT05336383 ·Status: RECRUITING ·Phase: PHASE2
-
Melphalan, Total Marrow Irradiation, and Autologous Stem Cell Transplantation in Treating Patients With High-Risk Multiple Myeloma
NCT03100877 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
A Study Assessing the Health-Related Quality of Life (HRQoL) in Participants With Relapsed and/or Refractory Multiple Myeloma (RRMM) With Triple Class Exposure
NCT05217082 ·Status: COMPLETED
-
Single Autologous Stem Cell Transplantation Followed by Maintenance Therapy as Front-line Treatment for Myeloma
NCT00892346 ·Status: SUSPENDED ·Phase: PHASE3
-
Safety and Efficacy Study of An Anti-CD38 Antibody Drug Conjugate in Relapsed or Refractory Multiple Myeloma
NCT05565807 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Efficacy of Response-adapted Treatment in Patients With Multiple Myeloma Candidates for Bone Marrow Transplantation
NCT05697913 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma
NCT00186238 ·Status: COMPLETED ·Phase: PHASE2
-
Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma
NCT02197221 ·Status: COMPLETED ·Phase: PHASE3